Towards precision monitoring in cancer care
AroCell’s vision is to bring precision monitoring to cancer care and help oncologists make appropriate and timely decisions on treatments for every patient. Our technologies will help to improve survival rates and the quality of life for patients, and reduce costs for healthcare providers.
AroCell TK 210 ELISA is CE-marked and designed to measure all forms of human TK1 in clinical blood samples allowing cell proliferation and disruption to be determined. The test can monitor the progression and remission of hematological malignancies such as lymphoma and leukemia, as well as solid tumors such as breast cancer.
We are focused on utilizing our proprietary technologies and know-how to make TK1 a standard biomarker that helps deliver improved survival rates and raise the quality of life in cancer care.
Validation, commercialisation and partnerships
We have three main missions:
To identify specific medical needs in the management of cancer disease.
We then validate our technologies and products to meet those medical needs and provide proof that our test can meet the requirements of improving care. We do this by performing clinical studies with clinicians and companies who share our goals.
To commercialize our technology by developing, producing, and marketing CE-marked ELISA kits to academic, clinical, and industrial research laboratories.
By offering a CE-marked TK1 assays we help clinical researchers integrate TK1 into a panel of tests for more precise monitoring of cancer patients. Our products are also valuable tools for use in drug discovery and development. Our first product is AroCell TK 210 ELISA.
To partner with in vitro diagnostic and pharmaceutical companies looking for liquid biopsy biomarkers to monitor the progression and regression of cancer tumors as a consequence of therapy as well as recurrence of disease.
This provides a route to global markets and gives us access to biomarker panels and automated hardware platforms already installed in hospitals, service labs, universities, and drug companies.